![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Centre National de la Recherche Scientifique, Formation de Recherche en Evolution 2855, Institut Fédératif de Recherches 37 Neurosciences, Strasbourg, France (S.C.); and Institut National de la Santé et de la Recherche Médicale, U575, Centre de Neurochimie, Strasbourg, France (D.C., C.G., P.A., C.B., J.-B.D., D.A., J.Z.)
Received January 9, 2006; accepted May 2, 2006
| Abstract |
|---|
|
|
|---|
Mutations within the MeCP2 gene, including large rearrangements, have been shown to be associated with Rett syndrome (RTT) in more than 85% of cases (Amir et al., 1999
; Shahbazian and Zoghbi, 2002
). RTT, a disorder found almost exclusively in women, is characterized essentially by severe cognitive impairment, autistic behavior, stereotypical handwringing movements, and seizures (Hagberg and Witt-Engerstrom, 1987
; Naidu, 1997
). The involvement of MeCP2 in methylation specific transcriptional repression suggests that symptoms of RTT are the consequence of inappropriate transcription of genes playing an important role for neuronal function.
In a recent ontogenetic study of the expression of Mecp2 protein in normal rat brain (Cassel et al., 2004
), we found significant heterogeneity in Mecp2 distribution between various brain areas. In structures including caudate putamen (CPu), septum, and hippocampus, very few cells showed detectable Mecp2 protein at birth. The number of immunoreactive cells increased during the first weeks of age, and neosynthesis of Mecp2 protein was still observed in some structures at the age of 2 years. However, the events by which spatiotemporal expression of Mecp2 is regulated remain poorly documented. In the present study, we looked for agents controlling Mecp2 expression in vivo and found that serotonin-elevating agents are able to induce its expression in adult rat brain.
| Materials and Methods |
|---|
|
|
|---|
Bioinformatics. GenBank contains two identical rat Mecp2_e2 coding DNA sequences (accession numbers M94064 [GenBank] and NM022673) and four associated expressed sequence tags (ESTs) that include neither the first exon encoding the N-terminal part of Mecp2_e1 nor the 5'-end of the second exon. In contrast, various mouse ESTs corresponding to the 5'-end of Mecp2_e1 were isolated using the NCBI blast program. Alignment of rat genomic sequence (accession number AC134952 [GenBank] ) with these mouse ESTs was performed to define the sequence of the rat Mecp2_e1 transcript.
Real-Time Quantitative PCR Analysis. Total RNA was extracted from dissected brain structures and first strand cDNA was generated from 1 µg of total RNA and random primers using Omniscript Reverse Transcriptase (QIAGEN, Valencia, CA) in a total volume of 20 µl in a 1-h reaction at 37°C. The reaction product was used for quantitative real-time PCR assay with a Light Cycler instrument and technology (Roche Applied Science, Indianapolis, IN) with SybR Green I dye for detection and 0.3 µM concentrations of appropriate primers. Rat Mecp2_e1 specific PCR was carried out using primer I (5'-GGAGAGACTGGAGGAAAAGTCA-3') and J (5'-CCTTCTTAAACTTCAGGGGTTTC-3') producing a PCR fragment of 74 bp. Rat Mecp2_e2 PCR was carried out using primer E (5'-CTGTTTGGGAGAAGCAGAGG-3') and primer F (5'-TGGTAGCTGGGATGTTAGGG-3'), producing a PCR fragment of 248 bp. MBD1 gene expression was measured using 5'-CAACCTTCCTGACTTCTTCCA-3' as a forward primer and 5'-GCCAATCCCTCCTATCTCTTC-3' as a reverse primer, and HDAC2 gene expression was measured using 5'-CCCTCAAACATGACAAACCA-3' as a forward primer and 5'-TGTCAGGGTCTTCTCCATCC-3' as a reverse primer. PCR comprised an initial denaturation step of 10 min at 95°C, followed by 45 cycles; one cycle consisted of 10 s at 95°C, 5 s at 65°C, and 10 s at 72°C. Clathrin was used as an internal control using 5'-AAGTATCCGTAAGTGGAG-3' as a forward primer and 5'-GGGGTTAAAGTCACACAG-3' as a reverse primer. Its amplification was performed in the same conditions as those used for Mecp2 transcripts except for an annealing temperature of 55°C.
Antibodies. The following rabbit polyclonal antibodies were used: anti-Mecp2 antibody (Upstate Biotechnology, Lake Placid, NY) prepared against amino acids 465 to 478 of mouse Mecp2_e2, diluted 1:200 in PBS; anti-MBD1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), diluted 1:200; anti-HDAC1 antibody (Upstate), diluted 1:500; anti-HDAC2 antibody (Upstate), diluted 1:400; and antibody specific for acetylated Lys-9 and Lys-14 on histone H3, diluted 1:250 (Upstate). Antibody binding was detected with secondary biotinylated horse anti-rabbit IgG. For confocal microscopy, mouse monoclonal anti-parvalbumin (Sigma), diluted 1:1000, was also used.
Immunohistochemistry. Immunohistochemistry was carried out as described previously (Cassel et al., 2004
). The percentage of immunoreactive cells in each structure was calculated from counts on at least 800 cells by an investigator blinded to the identity of the samples. For each value, 6 to 10 counts were performed on two serial sections from three to five rats. For confocal microscopy, brain sections were incubated overnight at room temperature with rabbit anti-Mecp2 together with monoclonal anti-parvalbumin antibodies. After washing, double staining was performed by incubating slides with Alexa Fluor 488-labeled anti-mouse antibody diluted 1:200 (Invitrogen, Carlsbad, CA) and rhodamine-labeled anti-rabbit antibody diluted 1:200 (Chemicon International, Temecula, CA) for 1 h. Images of labeled cells were acquired using a confocal laser scanning microscope (LSM 410 invert; Carl Zeiss Inc., Thornwood, NY). Nonspecific fluorescence was assessed by incubating cells with secondary antibodies alone and measuring the average intensity for each fluorochrome. This value was then subtracted from individual images.
|
| Results |
|---|
|
|
|---|
|
The data suggest that the serotonergic system was primarily involved because fluoxetine is a selective serotonin (5-HT) uptake inhibitor, whereas cocaine inhibits the 5-HT transporter together with the dopamine (DA) and the noradrenaline (NA) transporter (Ritz et al., 1990
). To further confirm this, we investigated whether GBR-12909 or nortriptyline (selective inhibitors of the DA and NA transporters, respectively) was able to induce the methyl-binding protein expression. Figure 3 shows quantitative analysis of the percentage of Mecp2 immunoreactive cells observed after treatment with these compounds in the same brain structures as those used to characterize the fluoxetine and cocaine effect. Repeated treatment for 10 days with both reuptake inhibitors was not found to significantly modify Mecp2 expression in the structures examined. Taken together, our data indicate that regulation of methyl-binding protein expression and HDAC activity results from an increase in extracellular 5-HT concentration.
|
|
|
To find out whether the increase of methyl-binding proteins resulted from an increase in the amount of mRNA, we measured mRNA expression of both Mecp2_e1 and Mecp2_e2 isoforms, as well as that of MBD1, by real-time quantitative PCR. Concerning Mecp2, position of primers relative to each transcript is illustrated in Fig. 5A. In addition, the N-terminal amino acid sequence of Mecp2_e1 deduced from the rat first exon was found to be highly homologous to that of the human and the mouse protein but revealed an unusual 24 alanine-long expansion encoded by GCC trinucleotide repeats (Fig. 5B). In agreement with what we found for the protein expression, no significant difference in Mecp2 or MBD1 mRNA synthesis could be observed upon a single fluoxetine injection to rats (Table 1). In contrast, the expression of the three transcripts was enhanced in response to repeated fluoxetine administration. Again, the effect was highest in the striatum in which Mecp2_e1, Mecp2_e2, and MBD1 mRNAs were increased by 98, 62, and 76%, respectively. Smaller although statistically significant increases in the amount of the Mecp2 mRNAs were found in frontal cortex and dorsal hippocampus, whereas MBD1 induction in the frontal cortex did not reach statistical significance. Using the same technique, we also found an increase in HDAC2 gene transcription in response to repeated fluoxetine administration; the most pronounced effect took place in the striatum (Table 1), thus confirming the increase in HDAC2 labeling intensity we observed immunohistochemically.
|
| Discussion |
|---|
|
|
|---|
Fluoxetine was the first molecule of a new generation of antidepressants, the selective serotonin-reuptake inhibitors, and is effective in the treatment of depression from the first week of therapy (Rossi et al., 2004
). Our findings, observed after a 10-day period of fluoxetine treatment but not in response to a single injection, therefore suggest that epigenetic regulation may be involved in its mode of action. In effect, genes the transcription of which is repressed by the epigenetic mechanism we describe may contribute to the antidepressant properties of fluoxetine.
5-HT neurons projecting from raphé nuclei ascend to the dopaminergic neuron projection fields in the forebrain, explaining the important effect we observe on methyl-CpG-binding protein synthesis in the striatum in response to enhanced 5-HT neurotransmission. Because 90% of the striatal neuronal population are medium spiny neurons that use GABA as their neurotransmitter (Kita and Kitai, 1988
), most of the neurons responding to fluoxetine in this structure by increasing Mecp2 levels are indeed GABAergic neurons. Important 5-HT projections are also taking place in the hippocampus (Parent et al., 1981
). In the DG, the raphé serotonergic projection terminates most heavily in the polymorphic layer, on a class of GABA interneurons that influence the firing of dentate granule cells (Halasy et al., 1992
). It is noteworthy that we found numerous cells in the hilus of the DG expressing high levels of Mecp2 in response to fluoxetine treatment, a number of them being characterized as GABAergic neurons. This observation suggests that Mecp2 plays an important role for the proper functioning of GABAergic interneurons of the DG. It provides a possible explanation for the occurrence of epileptic seizures commonly observed in RTT (Naidu, 1997
) because loss of hilar GABAergic interneurons is the most consistent deficit in patients and in experimental models of temporal lobe epilepsy (Buckmaster et al., 2002
).
The epigenetic regulation of gene expression seems to be crucial to the functional integrity of MeCP2-expressing GABAergic neurons. This is further supported by data from the literature, including those reported during the quest for target genes silenced by MeCP2. The maternally expressed Dlx5 gene showed a loss of imprinting in cells from persons with RTT (Horike et al., 2005
). Because Dlx5 regulates GABA synthesis, loss of imprinting of Dlx5 may therefore alter GABAergic neuronal activity in RTT. In addition, the GABRB3 gene, encoding the
3 subunit of GABAA receptor, showed reduced expression in multiple RTT and autism brain samples, as well as in Mecp2-deficient mice (Samaco et al., 2005
).
Accumulation of the methyl-binding proteins and a reduction in histone H3 acetylation suggest that 5-HT signaling is able to remodel chromatin structure, thereby controlling the accessibility of sequence-specific transcription factors to individual genes. Chromatin remodeling in response to cocaine has been shown to constitute an important regulatory mechanism underlying neural plasticity (Kumar et al., 2005
; Levine et al., 2005
). Hyperacetylation of histone H3 was observed with long-term cocaine treatment at the brain-derived neurotrophic factor and Cdk5 promoters, genes that are induced by long-term cocaine exposure (Kumar et al., 2005
). This is in contrast with the fact that MeCP2 has been shown to selectively bind to the BDNF promoter and repress expression of the BDNF gene (Chen et al., 2003
). The fact that several histone modifications can take place in concert at the same histone tail, corresponding to various states of remodeled chromatin (Cheung et al., 2000
), may help to explain the apparent discrepancy. Our data highlight the key role of methyl-CpG-binding proteins in this complex regulatory mechanism. Because the mechanism takes place in postmitotic neurons, they also indicate that these neurons are able to reinterpret the DNA methylation code they have acquired during early development.
| Acknowledgements |
|---|
| Footnotes |
|---|
Address correspondence to: Jean Zwiller, Unité INSERM U575, Centre de Neurochimie, 5 rue Blaise Pascal, 67084 STRASBOURG Cedex, France. E-mail: zwiller{at}neurochem.u-strasbg.fr
| References |
|---|
|
|
|---|
Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, and Zoghbi HY (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23: 185-188.[CrossRef][Medline]
Buckmaster PS, Yamawaki R, and Zhang GF (2002) Axon arbors and synaptic connections of a vulnerable population of interneurons in the dentate gyrus in vivo. J Comp Neurol 445: 360-373.[CrossRef][Medline]
Cassel S, Revel MO, Kelche C, and Zwiller J (2004) Expression of the methyl-CpG-binding protein MeCP2 in rat brain. An ontogenetic study. Neurobiol Dis 15: 206-211.[CrossRef][Medline]
Celio MR (1990) Calbindin D-28k and parvalbumin in the rat nervous system. Neuroscience 35: 375-475.[CrossRef][Medline]
Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, Jaenisch R, and Greenberg ME (2003) Derepression of BDNF transcription involves calciumdependent phosphorylation of MeCP2. Science (Wash DC) 302: 885-889.
Cheung P, Allis CD, and Sassone-Corsi P (2000) Signaling to chromatin through histone modifications. Cell 103: 263-271.[CrossRef][Medline]
Fan G and Hutnick L (2005) Methyl-CpG binding proteins in the nervous system. Cell Res 15: 255-261.[CrossRef][Medline]
Hagberg B and Witt-Engerstrom I (1987) Rett syndrome: epidemiology and nosologyprogress in knowledge 1986. Brain Dev 9: 451-457.[Medline]
Halasy K, Miettinen R, Szabat E, and Freund TF (1992) GABAergic interneurons are the major postsynaptic targets of median raphe afferents in the rat dentate gyrus. Eur J Neurosci 4: 144-153.[CrossRef][Medline]
Hendrich B and Bird A (1998) Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 18: 6538-6547.
Horike S, Cai S, Miyano M, Cheng JF, and Kohwi-Shigematsu T (2005) Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nat Genet 37: 31-40.[CrossRef][Medline]
Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, and Wolffe AP (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19: 187-191.[CrossRef][Medline]
Kita H and Kitai ST (1988) Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations. Brain Res 447: 346-352.[CrossRef][Medline]
Kriaucionis S and Bird A (2003) DNA methylation and Rett syndrome. Hum Mol Genet 12: R221-R227.
Kriaucionis S and Bird A (2004) The major form of MeCP2 has a novel N-terminus generated by alternative splicing. Nucleic Acids Res 32: 1818-1823.
Kumar A, Choi KH, Renthal W, Tsankova NM, Theobald DE, Truong HT, Russo SJ, Laplant Q, Sasaki TS, Whistler KN, et al. (2005) Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron 48: 303-314.[CrossRef][Medline]
Levine AA, Guan Z, Barco A, Xu S, Kandel ER, and Schwartz JH (2005) CREB-binding protein controls response to cocaine by acetylating histones at the fosB promoter in the mouse striatum. Proc Natl Acad Sci USA 102: 19186-19191.
Mnatzakanian GN, Lohi H, Munteanu I, Alfred SE, Yamada T, MacLeod PJ, Jones JR, Scherer SW, Schanen NC, Friez MJ, et al. (2004) previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nat Genet 36: 339-341.[CrossRef][Medline]
Naidu S (1997) Rett syndrome: a disorder affecting early brain growth. Ann Neurol 42: 3-10.[CrossRef][Medline]
Nan X, Campoy FJ, and Bird A (1997) MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88: 471-481.[CrossRef][Medline]
Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, and Bird A (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (Lond) 393: 386-389.[CrossRef][Medline]
Parent A, Descarries L, and Beaudet A (1981) Organization of ascending serotonin systems in the adult rat brain. A radioautographic study after intraventricular administration of [3H]5-hydroxytryptamine. Neuroscience 6: 115-138.[CrossRef][Medline]
Ritz MC, Cone EJ, and Kuhar MJ (1990) Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study. Life Sci 46: 635-645.[CrossRef][Medline]
Rossi A, Barraco A, and Donda P (2004) Fluoxetine: a review on evidence based medicine. Ann Gen Hosp Psychiatry 3: 2.[CrossRef][Medline]
Samaco RC, Hogart A, and Lasalle JM (2005) Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. Hum Mol Genet 14: 483-492.
Shahbazian M, Young J, Yuva-Paylor L, Spencer C, Antalffy B, Noebels J, Armstrong D, Paylor R, and Zoghbi H (2002) Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35: 243-254.[CrossRef][Medline]
Shahbazian MD and Zoghbi HY (2002) Rett syndrome and MeCP2: linking epigenetics and neuronal function. Am J Hum Genet 71: 1259-1272.[CrossRef][Medline]
Wade PA (2001) Methyl CpG binding proteins: coupling chromatin architecture to gene regulation. Oncogene 20: 3166-3173.[CrossRef][Medline]
Zhao X, Ueba T, Christie BR, Barkho B, McConnell MJ, Nakashima K, Lein ES, Eadie BD, Willhoite AR, Muotri AR, et al. (2003) Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal function. Proc Natl Acad Sci USA 100: 6777-6782.
Related articles in MolPharm:
This article has been cited by other articles:
![]() |
A. K. Percy Rett Syndrome: Recent Research Progress J Child Neurol, May 1, 2008; 23(5): 543 - 549. [Abstract] [PDF] |
||||
![]() |
S. C. Pandey, R. Ugale, H. Zhang, L. Tang, and A. Prakash Brain Chromatin Remodeling: A Novel Mechanism of Alcoholism J. Neurosci., April 2, 2008; 28(14): 3729 - 3737. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Newton and R. S. Duman Chromatin Remodeling: A Novel Mechanism of Psychotropic Drug Action Mol. Pharmacol., August 1, 2006; 70(2): 440 - 443. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||